ClinicalTrials.gg
BiologicalDrug

Nogapendekin alfa inbakicept clinical trials

Also written N-803, ALT-803 and Anktiva.

Its developmentBy ImmunityBio, step by step45 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
78
open now
18
in phase 3
5
first study started
2013

How each study uses nogapendekin alfa inbakicept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nogapendekin alfa inbakicept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Apr 2024 · ANKTIVA · BLA 761336 (FDA, Drugs@FDA)
European Union
16 Feb 2026 · Anktiva · EMEA/H/C/006622 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nogapendekin alfa inbakicept (NAI)
5
N803
4
NAI
3
Nogapendekin Alfa Inbakicept
3
N-803 (IL-15 Superagonist)
2

Brand

Anktiva
8

Development codes

N-803
34
ALT-803
30
Nant-803
1

Studies by the year they started

77 studies that test it; most in 2017 (17); 1 more planned to start later

Studies that test nogapendekin alfa inbakicept, by start year
YearStudies
20131
20144
20152
20162
201717
201814
20204
20215
20221
20232
20244
20257
202614

Who runs them

Industry 45 · Other 33

ImmunityBio, Inc. (39) · National Cancer Institute (NCI) (10) · Washington University School of Medicine (5) · Altor BioScience (5) · Masonic Cancer Center, University of Minnesota (5) · University of Minnesota (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Thai Red Cross AIDS Research Centre (1)

Often tested with

Tested in the same studies.

ETBX-011 (17) · ETBX-061 (17) · GI-4000 (16) · ETBX-051 (16) · GI-6301 (16) · Yeast-CEA vaccine (12) · ETBX-021 (8) · Albumin-Bound Paclitaxel (4)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6

Studies that test nogapendekin alfa inbakicept.

Studies

Open first, then newest update. How each study uses nogapendekin alfa inbakicept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 78

See all 78 studies that test nogapendekin alfa inbakicept →

Given beside what is tested · 15 — nogapendekin alfa inbakicept is usual care or a partner of the new treatment

Codes

What other systems call nogapendekin alfa inbakicept · ClinicalTrials.gg INT006311

  • MeSH (NLM) C582303nogapendekin alfa inbakiceptConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7TK323DLA0NOGAPENDEKIN ALFA INBAKICEPTConfirmed FDA, NLM
  • NCI Thesaurus C205507Nogapendekin Alfa InbakiceptOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.